Patient adherence and patient reported cognitive and health outcomes in patients using RebiSmart
Latest Information Update: 07 Dec 2018
Price :
$35 *
At a glance
- Drugs Interferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms READOUTsmart
- 07 Dec 2018 New trial record
- 28 Nov 2018 Results published in the Advances in Therapy